C

Cerapedics

Peptide-enhanced bone grafts for orthopedics

Overview

Cerapedics develops and commercializes peptide-enhanced bone grafts for orthopedic and spine procedures. Its flagship product, i-FACTOR Peptide Enhanced Bone Graft, combines a small P-15 peptide attached to anorganic bone mineral (ABM) to mimic the way autograft bone heals, promoting safe and predictable bone formation. The company differentiates itself by offering a biologically guided graft that relies on clinical data to support safety and efficacy, reducing the need for autograft harvest. Cerapedics aims to improve patient outcomes by providing clinicians with evidence-based graft solutions that enhance bone healing and fusion in bone grafting procedures.

Work here?Claim your company

About Cerapedics

Simplify's Rating
Why Cerapedics is rated
C+
Rated B on Competitive Edge
Rated B on Growth Potential
Rated D+ on Differentiation

Industries

Industrial & ManufacturingBiotechnologyHealthcare

Company Size

51-200

Company Stage

Late Stage VC

Total Funding

$150.9M

Headquarters

Westminster, CO

Founded

2000

Get referred to Cerapedics

See people who can refer or advise you

Simplify Jobs

Simplify's take

What believers are saying

  • CMS NTAP starts October 1, 2026, lowering hospital reimbursement friction for PearlMatrix adoption.
  • Cerapedics published 2026 Spine data showing PearlMatrix superiority over autograft in TLIF.
  • i-FACTOR's 2023 six-year cervical follow-up reported 98.6% fusion, strengthening surgeon trust.

What critics are saying

  • FDA MAUDE updated November 6, 2026, documenting i-FACTOR migration and nerve damage reports.
  • Off-label lumbar use creates surgical-migration liability and reimbursement scrutiny after the 2026 MAUDE report.
  • A PearlMatrix safety signal would freeze adoption and cripple the company's only growth engine.

What makes Cerapedics unique

  • i-FACTOR remains one of only two Cerapedics Class III spine grafts with Level 1 evidence.
  • PearlMatrix won CMS NTAP on October 1, 2026, validating its lumbar-fusion economics.
  • P-15 peptide branding links both products, creating a recognizable platform across cervical and lumbar surgery.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$150.9M

Above

Industry Average

Funded Over

8 Rounds

Late VC funding comparison data is currently unavailable. We're working to provide this information soon!
Late VC Funding Comparison Coming Soon

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • 401(k) Company Match
  • Remote Work Options
  • Paid Vacation
  • Paid Holidays
  • Performance Bonus

Growth & Insights and Company News

6 month growth

2%

1 year growth

1%

2 year growth

-6%
PR Newswire
Oct 1st, 2026
PearlMatrix bone graft receives Medicare add-on payment to accelerate lumbar fusion

Cerapedics' PearlMatrix P-15 Peptide Enhanced Bone Graft has received New Technology Add-on Payment status from the Centers for Medicare & Medicaid Services, effective 1 October 2026. The designation provides supplemental reimbursement to hospitals using novel technologies representing significant clinical advances. PearlMatrix is the first bone growth accelerator proven to accelerate lumbar fusion. A pivotal study showed more than twice as many patients achieved fusion at six months compared to those receiving local autograft alone, with higher fusion rates sustained at 12 and 24 months. The NTAP programme allows up to 65% reimbursement of additional costs for qualifying Medicare inpatient cases involving PearlMatrix. Cerapedics chief executive Valeska Schroeder said the approval may lower financial barriers for hospitals, allowing more patients access to the treatment. The product is indicated for intervertebral body fusion in skeletally mature patients with degenerative disc disease.

BIBA Medical Ltd
Oct 19th, 2023
Cerapedics announces long-term data from pivotal study of i-FACTOR bone graft

Cerapedics has announced long-term follow-up data from its pivotal investigational device exemption (IDE) study of the i-FACTOR peptide-enhanced bone graft.

BioSpace
Oct 17th, 2023
Cerapedics Reinforces Commitment To Level 1 Evidence With Long-Term Results From Six-Year Pivotal Ide Cervical Study Demonstrating 98.6% Spine Fusion Rates In Patients Treated With I-Factor®

WESTMINSTER, Colo., Oct. 17, 2023 /PRNewswire/ -- Cerapedics Inc., a commercial-stage orthopedics company dedicated to redefining the standard of care for bone repair, today announced long-term follow-up data from its pivotal IDE study of i-FACTOR Peptide-Enhanced Bone Graft. Published data demonstrated fusion rates in single-level Anterior Cervical Discectomy and Fusion (ACDF) of 98.6% after six years in patients treated with i-FACTOR and reinforces Cerapedics' commitment to capturing long-term clinical evidence. In particular, the results further support the safety and efficacy profile of i-FACTOR at one and two years, as published in Spine and Neurosurgery. . i-FACTOR has proven statistical superiority vs

Benzinga
Jul 19th, 2023
Cerapedics™ Announces Expansion Of Headquarters To Support Growth Of Its Bone Graft Products

WESTMINSTER, Colo., July 19, 2023 /PRNewswire/ -- Cerapedics Inc., a commercial-stage orthopedics company dedicated to redefining the standard of care for bone repair, announced today it is expanding its headquarters in the Denver metro area to support the growth of its products, which include the U.S. Food and Drug Administration (FDA)-approved i-FACTOR® bone graft for cervical spinal fusion and its next-generation product currently being evaluated for lumbar spinal fusion."Since the launch of i-FACTOR, we have seen a continuous increase in its use in spinal fusion. We are committed to supporting the needs of surgeons and their patients by expanding our facility," said Valeska Schroeder, Chief Executive Officer of Cerapedics. "We are fortunate to be based in Colorado and to recruit from the area's experienced, innovation-focused talent pool as we prepare to launch our next-generation product."i-FACTOR is the only spinal bone graft powered by P-15 Osteogenic Cell Binding Peptide™, and it is just one of two FDA approved Class III drug-device bone grafts with a spinal indication. i-FACTOR has proven statistical superiority vs. local autograft in overall success (defined as meeting Fusion, Function (Neck Disability Index), Neurological and Safety endpoints) at one and two-year endpoints for single-level Anterior Cervical Discectomy and Fusion.Cerapedics has fully enrolled its 290-patient randomized controlled clinical study evaluating the safety and efficacy of the next-generation P-15 Peptide Enhanced Bone Graft in transforaminal lumbar interbody fusion (TLIF) surgery

Colorful Dreams
Jul 19th, 2023
Cerapedics™ announces expansion of headquarters to support growth of its Bone Graft products

Cerapedics Inc., a commercial-stage orthopedics company dedicated to redefining the standard of care for bone repair, announced today it is expanding its headquarters in the Denver metro area to support the growth of its products, which include the U.S. Food and Drug Administration (FDA)-approved i-FACTOR® bone graft for cervical spinal fusion and its next-generation product currently being evaluated for lumbar spinal fusion.

Recently Posted Jobs

Sign up to get curated job recommendations

Cerapedics is Hiring for 6 Jobs on Simplify!

Find jobs on Simplify and start your career today

Don't see your dream role? Check out thousands of other roles on Simplify.Browse all jobs